Status:
RECRUITING
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
Lead Sponsor:
AbbVie
Conditions:
Chronic Migraine
Episodic Migraine
Eligibility:
All Genders
19+ years
Brief Summary
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the safety and effective...
Eligibility Criteria
Inclusion
- Participants with migraine suitable for the treatment with atogepant according to the latest approved local label.
- Participants prescribed atogepant in accordance with the approved local label.
Exclusion
- Participants with any contraindication to atogepant as listed on the latest approved local label.
- Participants currently participating in another clinical research except observational study.
Key Trial Info
Start Date :
September 24 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2029
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT06603558
Start Date
September 24 2024
End Date
May 1 2029
Last Update
April 10 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Hallym University Dongtan Sacred Heart Hospital /ID# 273581
Hwaseong, Gyeonggido, South Korea, 18450
2
Seoul National University Hospital /ID# 271892
Seoul, Seoul Teugbyeolsi, South Korea, 03080
3
Kangbuk Samsung Hospital /ID# 271893
Seoul, Seoul Teugbyeolsi, South Korea, 03181
4
Yonsei University Health System Severance Hospital /ID# 272639
Seoul, Seoul Teugbyeolsi, South Korea, 03722